Foundation Medicine to Present at the Wedbush 2014 Life Sciences Conference

Foundation Medicine Announces 2014 Second Quarter Results and Recent Highlights

Zafgen to Present at 34th Annual Canaccord Genuity Growth Conference

Agios Pharmaceuticals Reports Second Quarter 2014 Financial Results

Foundation Medicine Appoints Lisa Ricciardi Senior Vice President, Corporate and Business Development

SAGE Therapeutics to Present at Canaccord Genuity 34th Annual Growth Conference

Zafgen to Host Conference Call to Discuss Second Quarter 2014 Financial Results

Blueprint Medicines to Present at Wedbush 2014 Life Sciences Management Access Conference

bluebird bio to Present at Two Upcoming Health Care Conferences

Constellation Expands Clinical Studies of CPI-0610

Global Blood Therapeutics Names Hing Sham Senior Vice President of Chemistry, Promotes Uma Sinha to Chief Scientific Officer

Eleven Biotherapeutics to Report Second Quarter 2014 Financial Results on August 13, 2014

Dinah Sah, Senior Vice President of Neuroscience and Rob Kotin, Vice President of Production Honored Among PharmaVOICE 100 Most Inspiring People

Kala Pharmaceuticals Initiates Phase 2 Clinical Trial to Evaluate LE-MPP (KPI-121) in Patients with Retinal Vein Occlusion and Diabetic Macular Edema

Foundation Medicine Releases Enhanced Version of FoundationOne®

Eleven Biotherapeutics to Present at Wedbush 2014 Life Sciences Management Access Conference

Agios Pharmaceuticals to Webcast Conference Call of Second Quarter 2014 Financial Results on August 7, 2014

Blueprint Medicines Appoints Jeffrey Albers as Chief Executive Officer

Foundation Medicine Partners with the Addario Lung Cancer Medical Institute for Innovative Prospective Study Linking the Genomic Drivers of Lung Cancer in Young Adults with Treatment Options

SAGE Therapeutics Announces Closing of Initial Public Offering

SAGE Therapeutics Receives Fast Track Designation for Lead Compound SAGE-547 to Treat Status Epilepticus

SAGE Therapeutics Announces Full Exercise of Over-Allotment Option

Foundation Medicine Receives Approvals from New York State Department of Health for FoundationOne® and FoundationOne Heme®

SAGE Therapeutics Announces Pricing of Initial Public Offering

Foundation Medicine Announces Timing for Second Quarter 2014 Financial Results and Conference Call

bluebird bio Appoints Mark Vachon to its Board of Directors

Jounce Therapeutics Appoints Richard Murray, Ph.D., to Chief Executive Officer

DC Devices Closes $34M Series D Financing to Complete Clinical Evaluation of the First Transcatheter Device to Treat Diastolic Heart Failure

bluebird bio Acquires Precision Genome Engineering, a Privately Held Gene-Editing Company

Foundation Medicine Offers FoundationOne® CareLine to Provide Personalized Assistance to Cancer Patients Seeking Access to Targeted Therapies

Voyager Therapeutics Appoints Industry Veteran Robert G. Pietrusko, Pharm.D., to Senior Vice President of Regulatory Affairs

Zafgen Appoints New Member of Board of Directors

Zafgen, Inc. Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option

Editas Medicine Appoints Katrine S. Bosley to Chief Executive Officer

Rhythm Presents Clinical Data that RM-493 Increases Energy Expenditure in Obesity Study

Blueprint Medicines to Present at JMP Securities Healthcare Conference

Kala Pharmaceuticals Initiates Phase 3 Clinical Trial for Treatment of Post-Surgical Ocular Inflammation and Phase 2 Clinical Trial in Dry Eye Disease

Global Blood Therapeutics Names Ted W. Love as CEO

Groundbreaking Collaborative Clinical Trial Launched

Agios Pharmaceuticals Announces Orphan Drug Designation of AG-221 for Treatment of Acute Myelogenous Leukemia

New Agios Clinical Data from Ongoing Phase 1 Trial of AG-221 Continue to Show Complete and Durable Remissions in Patients with Difficult to Treat Hematologic Malignancies

bluebird bio Reports Rapid Transfusion Independence in Beta-Thalassemia Major Patients Treated with its LentiGlobin Product Candidate

Agios Pharmaceuticals Announces that Celgene Exercised its Option to License AG-221 Under Global Strategic Collaboration

NinePoint Medical Receives 2014 MDEA Silver Medal for NvisionVLE Imaging System Deficiency, a Rare, Hemolytic Anemia

SAGE Therapeutics Appoints James M. Frates to the Company’s Board of Directors

Agios Pharmaceuticals Initiates Multiple Ascending Dose Trial in Healthy Volunteers of AG-348 for the Potential Treatment of PK

bluebird bio to Host a Conference Call to Discuss Initial Results from the HGB-205 Study in Beta-Thalassemia Major Subjects

SAGE Therapeutics Presents Preliminary SAGE-547 Clinical Data at Epilepsy Pipeline Conference

Bristol-Myers Squibb and CytomX Therapeutics Announce Worldwide Collaboration to Develop Probody™ Therapeutics Against Multiple Immuno-Oncology Targets

Third Rock Ventures and The Column Group Launch Nurix with $25.1 Million Financing to Target Key Regulatory Pathway